Interview with the Innovators

Interview with the Innovators

Web Exclusives | December 10, 2021
Dr Steven Rowe expands on the sensitivity and specificity of PYLARIFY® (piflufolastat F 18) imaging in high-risk prostate cancer.
A series of interviews was recently conducted with a panel of experts on prostate cancer imaging modalities that included Steven Rowe, MD, PhD, Associate Professor of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, and Neal D. Shore, MD, FACS, CMO, Surgical Oncology/Urology Genesis Care, US; Director, CPI, Carolina Urologic Research Center, Myrtle Beach, SC.
Web Exclusives | December 2, 2021
Dr Neal Shore emphasizes the importance of accurate staging of prostate cancer and how PYLARIFY® (piflufolastat F 18) can improve treatment decision-making in patients with prostate cancer.
Web Exclusives | November 23, 2021
Dr Neal Shore highlights example patient populations that may benefit from improved staging through the use of PYLARIFY® (piflufolastat F 18), a prostate-specific membrane antigen (PSMA)-targeted PET/CT agent.
Web Exclusives | November 15, 2021
Dr Neal Shore discusses the importance of PSMA PET imaging across a range of PSA values and how PYLARIFY® (piflufolastat F 18) will affect imaging of patients with oligometastatic prostate cancer.
Video Library | November 8, 2021
Dr Neal Shore elaborates on the ability of PYLARIFY® (piflufolastat F 18) to detect metastases and the practical aspects of next-generation imaging.
Video Library | November 1, 2021
Dr Neal Shore discusses the rationale of prostate-specific membrane antigen (PSMA) PET/CT to guide prostate cancer treatment.
Video Library | November 1, 2021
Combinations of agents have replaced sunitinib as first-line therapy for advanced renal-cell cancer. Laura Wood, RN, MSN, OCN; Megan Price, MSN, APRN, FNP-C; and Virginia Seery, MSN, RN, ANP-BC, AOCNP, discuss their best practices for helping patients get the most benefit out of combination therapy for their advanced renal-cell cancer diagnosis.
Video Library | October 20, 2021
Dr Neal Shore introduces the current global landscape of various imaging modalities for prostate cancer, including a new prostate-specific membrane antigen (PSMA)-targeted PET/CT agent, PYLARIFY® (piflufolastat F 18).
Video Library | October 8, 2021
Laura Wood, RN, MSN, OCN; Megan Price, MSN, APRN, FNP-C; and Virginia Seery, MSN, RN, ANP-BC, AOCNP, discuss strategies for addressing patients’ concerns about how combination therapy may impact their activities of daily living and quality of life.
Page 1 of 10
Results 1 - 10 of 91

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code